| Date | Company | Compound | Disease | Type of agreement | Therapeutic area | Type of Information |
|---|---|---|---|---|---|---|
| 2013-03-22 | Bio-Modeling Systems (France) Persistent Systems (USA) | predictive in silico or computer simulated skin model | collaboration |
Collaboration agreement | ||
| 2013-03-21 | AstraZeneca (UK) Moderna Therapeutics (USA) | messenger RNA therapeutics™ | cardiovascular diseases, metabolic diseases, renal diseases, cancer | R&D |
Cardiovascular diseases - Cancer- Oncology - Metabolic diseases - Renal diseases | R&D agreement |
| 2013-03-20 | MediGene (Germany) SynCore Biotechnology (Taiwan) | Veregen® ointment (made from the extract of green tea leaves - catechins) | External genital warts | commercialisation |
Infectious diseases - Gynecology - Women's health | Commercialisation agreement |
| 2013-03-19 | Leo Pharma (Denmark) National Psoriasis Foundation (USA) | psoriasis | collaboration |
Autoimmune diseases - Dermatological diseases | Collaboration agreement | |
| 2013-03-19 | UCB (Belgium) Five Prime Therapeutics (USA) | potential drug targets and drug candidates in fibrosis-related inflammatory diseases and CNS disorders | fibrosis-related inflammatory diseases, central nervous system disorders | R&D |
CNS diseases - Inflammatory diseases | R&D agreement |
| 2013-03-18 | Merck KGaA, Merck Serono (Germany) Nordic Bioscience (Denmark) | sprifermin (recombinant human fibroblast growth factor (FGF)-18) | osteoarthritis of the knee | R&D - clinical research | Rheumatic diseases - Inflammatory diseases – Bone diseases | Clinical research agreement |
| 2013-03-18 | GSK (UK) Proteologics (Israel) | small molecule inhibitors of the ubiquitin system | undisclosed | R&D |
undisclosed | R&D agreement |
| 2013-03-14 | Spectrum Pharmaceuticals (USA - NV) Ligand Pharmaceuticals (USA - CA) | Captisol-Enabled Melphalan (CE-Melphalan) HCl for injection (propylene glycol-free) | multiple myeloma | Cancer - Oncology | Establishment of a new subsidiary in the EU | |
| 2013-03-13 | Sistemic (UK) Progenitor Cell Therapy (USA) | SistemQC™ stem cell characterisation technology | collaboration |
Collaboration agreement | ||
| 2013-03-13 | Oxford Gene Technology (UK) Institute of Cancer Research (ICR) (UK) | diagnostic and prognostic microRNA biomarkers for prostate cancer | prostate cancer | licensing |
Cancer - Oncology | Licensing agreement |
| 2013-03-13 | Boehringer Ingelheim (Germany) Presidio Pharmaceuticals (USA) | oral combination of HCV NS5A inhibitor (PPI-668) with faldaprevir (BI201335) and BI207127 | hepatitis C | clinical research |
Infectious diseases | Clinical research agreement |
| 2013-03-13 | Genable Technologies (Ireland) | nomination |
Rare diseases - Genetic diseases - Ophtalmological diseases | Nomination | ||
| 2013-03-12 | LeicaBiosystems (Germany) Synthon Biopharmaceuticals (The Netherlands) | companion diagnostic test for solid tumors | solid tumors |
development |
Cancer - Oncology | Development agreement |
| 2013-03-12 | Orion Corporation (Finland) Gedeon Richter (Hungary) | new chemical entities in the field of cognitive disorders | cognitive disorders | R&D |
CNS diseases | R&D agreement |
| 2013-03-12 | the Max Planck Institute of Biochemistry (MPIB) (Germany) The Lead Discovery Center (LDC) (Germany) Qurient (South Korea) | kinase inhibitor for the treatment of metastatic cancer | licensing |
Cancer - Oncology | Licensing agreement | |
| 2013-03-11 | Sirona Biochem (Canada) Vitamfero (France) | preservation technology | collaboration |
Infectious diseases - Veterinary medicine | Collaboration agreement | |
| 2013-03-11 | Neurovive Pharmaceutical (Sweden) Biotica (UK) | portfolio of sangamides, cyclophilin inhibitors | acquisition | Cardiovascular diseases - CNS diseases | ||
| 2013-03-11 | Clinigen (UK) Theravance (USA) | Vibativ® (telavancin) | nosocomial pneumonia (hospital-acquired), including ventilator-associated pneumonia, known or suspected to be caused by methicillin resistant Staphylococcus aureus (MRSA) when other alternatives are not suitable. | commercialisation |
Infectious diseases | Commercialisation agreement |
| 2013-03-08 | Galapagos (Belgium) Roche (Switzerland) | fibrosis | R&D | |||
| 2013-03-07 | Cellectis (France) Stemgent (USA) | custom genome-engineered iPS cells | collaboration |
Services contract |
